Alzheimer's Disease with Agitation and Aggression — Next Step When Citalopram Has Not Achieved Adequate Control
Clinical Scenario
This protocol addresses agitation and aggression occurring in a person with Alzheimer's disease. Only a limited number of medications are formally licensed for this behavioural presentation in dementia, making structured selection critical.
Previous Treatment Did Not Achieve Goals
An initial course of citalopram — started after a baseline ECG assessment — did not produce a significant reduction in the frequency of agitation episodes after 4 weeks. That unmet threshold triggers escalation to this next-line protocol.
Next-Line Approach (Partial Overview)
The structured next step involves switching to an atypical antipsychotic using a carefully managed transition scheme, with close monitoring throughout. The complete selection criteria, switching procedure, and monitoring requirements are set out in the full protocol.
Target outcome: Reduction of agitation and aggression, with benefits typically evident after at least 4 weeks.
References
DOI: 10.1016/S0140-6736(25)01329-7
- Only the atypical antipsychotics risperidone (Europe and Canada) and brexpiprazole (USA, Canada, and Switzerland), and the typical antipsychotic haloperidol (Germany), are licensed for the treatment of agitation aggression for people with dementia.
- Following a risk–benefit assessment, person C is switched to risperidone over 4 weeks with a cross-taper switch scheme. Brexpiprazole would have been equally indicated.
- Doses of risperidone or brexpiprazole should be started low and increased over 2–4 weeks to identify the lowest effective dose, with careful monitoring for oversedation, reduced mobility, or other adverse effects.
- Personal experience and evidence from the literature suggest that citalopram and atypical antipsychotics, such as quetiapine, confer small, but significant, benefits for agitation, at least for the first 3 months of treatment, and even smaller benefits are found for psychosis.
- As it usually takes at least 4 weeks for the benefits of slow-tapering antipsychotic medication to become evident, it is also important to help to reduce potential triggers—eg, by enabling person C to spend more time in a quiet lounge or his room (with regular interaction).
View source ↗